---
title: "Shandong Xinhua Pharmaceutical erhält Zulassung für Glucosamin-Sulfat-Kapseln in China"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275286831.md"
description: "Shandong Xinhua Pharmaceutical Company Ltd. has received regulatory approval for Glucosamine Sulfate capsules in China. The approval was granted under the Drug Administration Law of the People's Republic of China after review. The product is classified as an over-the-counter medication of category A. Production and sales can only commence after compliance with applicable pharmaceutical manufacturing standards. No other organizations are mentioned in the announcement."
datetime: "2026-02-09T08:33:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275286831.md)
  - [en](https://longbridge.com/en/news/275286831.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275286831.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275286831.md) | [繁體中文](https://longbridge.com/zh-HK/news/275286831.md)


# Shandong Xinhua Pharmaceutical erhält Zulassung für Glucosamin-Sulfat-Kapseln in China

Die Shandong Xinhua Pharmaceutical Company Ltd. hat die behördliche Zulassung für Glucosamin-Sulfat-Kapseln zur Suspension erhalten. Die Genehmigung wurde gemäß dem Arzneimittelgesetz der Volksrepublik China nach Prüfung erteilt. Das Produkt wird als nicht verschreibungspflichtiges Arzneimittel der Kategorie A eingestuft. Die Produktion und der Verkauf dürfen erst nach Einhaltung der geltenden Standards für die Herstellung von Arzneimitteln erfolgen. Weitere Organisationen neben Shandong Xinhua Pharmaceutical Company Ltd. werden in der Ankündigung nicht genannt. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Xinhua Pharmaceutical Company Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260209-12019080), on February 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/en/quote/512010.CN.md)
- [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/en/quote/513120.CN.md)
- [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/en/quote/159316.CN.md)
- [Guotai SSE STAR Brand Name Drug ETF (589720.CN)](https://longbridge.com/en/quote/589720.CN.md)
- [Bosera Hang Seng Health Care ETF(QDII) (513060.CN)](https://longbridge.com/en/quote/513060.CN.md)
- [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/en/quote/159506.CN.md)
- [Hwabao WP CSI Pharmaceuticals ETF (562050.CN)](https://longbridge.com/en/quote/562050.CN.md)
- [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/en/quote/159992.CN.md)
- [China Universal CNI HK Connect Innovative Drugs Industry ETF (159570.CN)](https://longbridge.com/en/quote/159570.CN.md)
- [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/en/quote/512290.CN.md)
- [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/en/quote/520880.CN.md)
- [Penghua CSI HK Connect Health Care Composite ETF (513700.CN)](https://longbridge.com/en/quote/513700.CN.md)
- [Xinhua Pharm (000756.CN)](https://longbridge.com/en/quote/000756.CN.md)
- [Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII) (520500.CN)](https://longbridge.com/en/quote/520500.CN.md)
- [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/en/quote/520690.CN.md)
- [SHANDONG XINHUA (00719.HK)](https://longbridge.com/en/quote/00719.HK.md)
- [China Universal 800 Health Care ETF (159929.CN)](https://longbridge.com/en/quote/159929.CN.md)
- [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/en/quote/588130.CN.md)
- [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/en/quote/510660.CN.md)

## Related News & Research

- [Henlius Biotech Doses First Patient in Phase 2/3 Breast Cancer Drug Study; Shares Slip 3%](https://longbridge.com/en/news/277421361.md)
- [Shandong Xinhua Pharmaceutical Receives Drug Registration Certificate for Glucosamine Sulfate Capsules](https://longbridge.com/en/news/275286848.md)
- [08:03 ETDecentralized Clinical Trial Validates Novel "Fasting Mimetic" Formulation for Cardiometabolic Health](https://longbridge.com/en/news/277468910.md)
- [Sanofi bets on Sino Biopharm’s transplant drug in $1.5bn licensing deal](https://longbridge.com/en/news/277818646.md)
- [Hengrui Pharmaceuticals Gets Clinical Trial Nod for Hypertension Drug](https://longbridge.com/en/news/277870666.md)